Biotech Daily

Tuesday July 14, 2026

Daily news on ASX-listed biotechnology companies

*** ASX EVEN, BIOTECH DOWN: RESONANCE UP 9%; IMPEDIMED DOWN 17%**

*** AROA: CMS $184/cm^2 SKIN SUBSTITUTE REIMBURSEMENT**

*** NEUROTECH FDA NTI164 AUTISM IND APPROVAL**

*** PACIFIC EDGE Q1 CXBLADDER TESTS DOWN 35% TO 5k; $245k LOSS**

*** MESOBLAST TREATS REXLEMESTROCEL-L LOW BACK PAIN TRIAL**

*** OSTEOPORE DELIVERS 1st DEVICE TO HAINAN HOSPITAL**

*** BLINKLAB EXPECTS 5 STUDY RESULTS THIS YEAR, 5 in 2027**

*** IMMUTEP WINS 4th US EFTI PATENT**

*** RECCE VIETNAM R327, R529 PATENT FAMILY**

*** EMVISION 'EMU' STROKE DATA PUBLICATION**

*** HERAMED, LEE HEALTH COMPLETE PHASE ONE HERACARE PROGRAM**

MARKET REPORT

The Australian stock market was flat on Tuesday July 14, 2026 with the ASX200 unchanged at 8,808.5 points (the All Ordinaries slipped 1.7 points or 0.02 percent to 9,001.3 points). Fifteen of the Biotech Daily Top 40 companies were up, 21 fell and four traded unchanged.

Resonance was the best, up 0.4 cents or 9.3 percent to 4.7 cents, with 100,000 shares traded. Proteomics rose 8.3 percent; Curvebeam and Prescient climbed more than six percent; Saluda was up five percent; Atomo and Starpharma were up three percent or more; Dimerix rose 2.1 percent; Aroa, Cochlear, CSL, Emvision, Medical Developments, Mesoblast and Neuren were up more than one percent; with Artrya, Polynovo and Resmed up by less than one percent.

Impedimed led the falls, down 0.1 cents or 16.7 percent to 0.5 cents, with 2.5 million shares traded. Imricor and Paradigm lost more than eight percent; Orthocell was down 6.5 percent; Actinogen, Lumos and Nova Eye fell more than four percent; Amplia and EBR were down more than three percent; Pro Medicus and Syntara shed more than two percent; 4D Medical, Alcidion, Cyclopharm, Immutep, Imugene, Racura and Telix were down one percent or more; with Avita, Clarity, Clinuvel and Nanosonics down by less than one percent.

AROA BIOSURGERY

Aroa says the CMS has implemented a single payment rate for outpatient skin substitute reimbursement of $US127.14 ($A183.61) per square centimetre.

Aroa said the US Centers for Medicaid & Medicare Services (CMS) change had “led to a major disruption in this market due to price compression and more patients being treated in the hospital outpatient department rather than other sites of care”.

The company said indications were “that companies with business models predicated on inflated pricing may exit, and the advantage is likely to shift to products that can demonstrate strong value and high-quality clinical evidence”.

Aroa said its sheep stomach-based Symphony met both requirements and its hospital-based sales team and surgical portfolio meant the company was well-placed to benefit from this new environment.

Last year, the company said updated CMS local coverage determinations allowed its Symphony skin graft for foot and leg ulcers to be covered until “at least the end of 2026” (BD: Dec 19, 2025).

Today, Aroa said healthcare providers and manufacturers had expected further refinements could be made by CMS for 2027, but CMS indicated “its intent to maintain the current single payment rate”.

The company said CMS noted that revising rates for 2027 before the 2026 rates were reflected in claims data “could create payment disruption and unnecessary volatility”.

Aroa said despite disruption in the outpatient skin substitute market, “continuation of the current payment framework provides an important period of stability”.

Aroa managing-director Brian Ward said the proposal to maintain the payment framework for 2027 provided “clarity for the outpatient skin substitute market”.

“We believe Symphony is well placed as the market re-establishes itself, supported by responsible pricing and [a randomized controlled trial] that we expect to publish in the coming months,” Mr Ward said.

“We are confident our investment in Symphony will deliver growth in the medium term,” Mr Ward said. “The proposed rule applies to hospital outpatient departments and ambulatory surgical centres and does not impact reimbursement for Myriad products, whose primary market is the hospital inpatient setting under a different reimbursement framework.”

Aroa was up one cent or 1.7 percent to 59.5 cents.

NEUROTECH INTERNATIONAL

Neurotech says it has US Food and Drug Administration investigational new drug approval for US development of NTI164 marijuana for autism spectrum disorder.

Neurotech said clearance allowed it to begin its proposed clinical development program for NTI164 in the US and was “a major regulatory milestone for the company”.

The company said the submission included its chemistry, manufacturing and controls, non-clinical and clinical information supporting the clinical and development program.

Neurotech said the study would be a comprehensive population pharmaco-kinetic program designed to complement its Australian phase III trial, which was “intended to generate pivotal efficacy and safety data for NTI164 in paediatric [autism] patients”.

Earlier this year, the company said it opened the first site in its 150-patient, phase III trial of NTI164 marijuana for autism spectrum disorder (BD: Mar 17, 2026).

Today, Neurotech said the two trials were “expected to generate an integrated efficacy, safety, pharmacokinetic and regulatory data package to support Neurotech's global development, registration and commercialization strategy for NTI164”.

Neurotech was up 0.1 cents or 6.25 percent to 1.7 cents with 21.4 million shares traded.

PACIFIC EDGE

Pacific Edge says Cxbladder tests for the three months to June 30, 2026 fell 34.9 percent to 5,116 tests and it reduced its cash burn to $NZ170,000 ($A245,000).
Earlier this year, Pacific Edge said Cxbladder urine tests for bladder cancer processed for the year to March 31, 2026 fell 16.2 percent to 24,208 tests, compared to the previous corresponding period (BD: Apr 10, 2026).
Later, the company said revenue for the year to March 31, 2026 fell 47.25 percent to $NZ11.5 million, with net loss after tax of $NZ35.8 million (BD: May 25, 2026).
Today, Pacific Edge said it disclosed its total laboratory throughput and US commercial tests but did not state whether they were additive nor the revenue for the three months.
Pacific Edge chief executive officer Dr Peter Meintjes said the three-month results of Asia Pacific operations showed "key results that we aim to replicate in the US".
"Transition to Triage Plus and a focus on the strategic selling of clinical pathways to institutions has led to several quarters of consistent growth in commercial testing volume, revenue, margin and margin percentage," Dr Meintjes said.
"In the US, Novitas' draft local coverage determination published on May 14 'Urine-based Biomarkers in Patients with Microhaematuria', has created the opportunity for similar success," Dr Meintjes said.
"With selective investments in our commercial and digital teams, we are seeking to target integrated delivery networks such as academic centres and hospital systems with clinical pathways for Triage Plus and re-focus our account executives on intermediate risk microhaematuria patients where our value proposition is clearer, and our commercial strategy can be rebuilt around reimbursable use," Dr Meintjes said.
Last year, the company said local coverage determination changes by Medicare administrative contractor (MAC) Novitas halted coverage of Cxbladder (BD: Apr 28, 2025).
Earlier this year, Pacific Edge rose 44.8 percent on the publication of a draft local coverage determination (LCD) with explicit coding guidance for its Cxbladder Triage and Triage Plus tests (BD: May 15, 2026).
Pacific Edge was unchanged at 24 cents.

MESOBLAST

Mesoblast says it has treated more than 300-patients in its phase III trial of rexlemestrocel-L for chronic low back pain associated with degenerative disc disease.
In 2021, Mesoblast said that a 404-patient, phase III, randomized, controlled trial of rexlemestrocel-L, with and without hyaluronic acid compared to placebo, "did not reach statistical significance across the entire study" for low back pain (BD: Feb 11, 2021).
In 2024, the company said it had begun a 300-patient, phase III trial of rexlemestrocel-L for degenerative disc disease-related chronic low back pain; and earlier this year, said it had recruited the trial (BD: Jul 22, 2024; Apr 29, 2026).
Today, Mesoblast said the trial aimed "to confirm the durable pain reduction from a single intra-discal injection of rexlemestrocel-L".
The company said topline results were "expected in mid-2027 after the last treated patient has completed 12 months follow-up".
Mesoblast chief executive Prof Silviu Itescu said "completing the target of treating at least 300 patients in the placebo-controlled, pivotal, back pain trial ensures the trial is well-powered for success".
"Commercial manufacturing is proceeding in parallel so that we can file for approval as soon as possible after trial results readout," Prof Itescu said.
Mesoblast was up three cents or 1.3 percent to $2.38 with 5.4 million shares traded.

OSTEOPORE

Osteopore says it has delivered its first custom orthopaedic device for commercial patient use to the Hainan branch hospital of Shanghai Ruijin Hospital, China.
Earlier this year, Osteopore said that it had Hainan Products Administration approval in China for the clinical use of its orthopaedic custom medical devices at the Shanghai Ruijin Hospital (BD: May 26, 2026).
Osteopore chief executive officer Dr Yujing Lim told Biotech Daily that the device was approved for “patient-specific bone reconstruction” but did not nominate which bone.
Osteopore was unchanged at 0.5 cents.

BLINKLAB

Blinklab says it expects readouts from five study programs relating to its Dx1 diagnostic during 2026, followed by five additional readouts in 2027.
Blinklab said expected results included diagnostic and monitoring trials on paediatric and adult attention deficit hyperactivity disorder (ADHD), autism, early dementia and spino-cerebellar ataxia.
Blinklab managing-director Dr Henk-Jan Boele said the “first commercial priority remains obtaining [US Food and Drug Administration] clearance for Blinklab Dx1 in the US”.
“At the same time, we believe the long-term opportunity for Blinklab extends well beyond a single product,” Dr Boele said.
“Our platform enables us to deliver a broad range of well-established neuro-metric assessments through a smartphone, making it possible to collect objective data at a scale that has not previously been practical using conventional laboratory equipment,” Dr Boele said. “We are deliberately focusing on conditions where decades of neuroscience research have already established a strong biological foundation.”
“Rather than starting from scratch, we are translating proven laboratory paradigms into a scalable smartphone platform that can validate these findings in larger and more clinically representative populations,” Dr Boele said.
Blinklab fell 1.5 cents or 2.4 percent to 62 cents.

IMMUTEP

Immutep says the US Patent and Trademark Office has granted it a fourth patent protecting its eftilagimod alfa, or efti, and related intellectual property.
Immutep said the patient, titled ‘Combined Preparations for the Treatment of Cancer or Infection’ would protect its intellectual property until January 20, 2026.
Immutep fell 0.1 cents or 1.8 percent to 5.5 cents with 26.5 million shares traded.

RECCE PHARMACEUTICALS

Recce says the Intellectual Property Office of Vietnam has granted patent Family 4 for its anti-infectives including R327 and R529.
Recce said the patent family protected its intellectual property until 2041 and related to R327 and R529 including process for preparation, use in bacterial and viral infections as well as administration by oral, inhalation, transdermal delivery or injection.
The company said the grant was the eighth Family 4 patent alongside Australia, Canada, China, Hong Kong, Israel, Japan and Brazil with further patent submissions in additional jurisdictions in respective stages of review.
Recce fell half a cent or 1.3 percent to 38.5 cents.

EMVISION MEDICAL DEVICES

Emvision says data from its 307-participant study of its 'Emu' brain scanner shows it differentiates ischaemic and haemorrhagic stroke.

In 2024, Emvision said a 307-participant study showed its artificial intelligence (A.I.)-based Emu brain scanner had 85 percent sensitivity and 78 percent specificity for diagnosing patients with ischemic strokes (BD: Nov 12, 2024).

Last year, the company said its 'Emu' scanner determined ischaemic or non-ischaemic stroke with 95 percent sensitivity and 80 percent specificity and determined haemorrhagic or non-haemorrhagic stroke with 92 percent sensitivity and 85 percent specificity (BD: May 21, 2025).

Today, Emvision said the publication, titled 'Portable RF brain scanner enables deep-learning-based stroke type detection and ordering of brain-event dielectric permittivity' was published in Nature Partner Journals at: https://bit.ly/4gxwEac.

Emvision was up two cents or 1.3 percent to $1.525.

HERAMED

Heramed says it has completed phase one of its Heracare foetal heart rate monitor pilot program for pregnant women with the Fort Myers, Florida-based Lee Health.

Last year, Heramed said it would conduct a $US115,000 ($A176,000) pilot program of its Heracare maternity care device and software with Lee Health (BD: Nov 27, 2025).

At the time, the company said following a successful pilot program it expected to "implement commercial pricing and expand the deployment with Lee Health to support the phase two scale-up to onboard 2,000 pregnancies managed by Lee Health annually".

Today, Heramed said results from the first phase of the study showed the "hybrid maternity care model is feasible, well accepted by patients and capable of supporting a more efficient pregnancy care pathway".

The company said 44 patients completed virtual pre-natal visits, with "92 percent virtual adoption, 100 percent likelihood to recommend … [net promoter score] of 60 and [remote patient monitoring] device [net promoter score] of 75".

Heramed said that "modelled outcomes indicate … [its pregnancy care system] may free three to five pre-natal appointment slots per patient, supporting improved access and operational efficiency, creating 32 additional pre-natal slots".

The company said with Lee Health it was "progressing final internal sign-off for phase two, with a decision targeted in the coming weeks".

Heramed fell 0.3 cents or 7.7 percent to 3.6 cents with 1.05 million shares traded.